Currently Viewing:
NCCN 22nd Annual Conference
Dr Moon S. Chen Jr Explains the Far-Reaching Benefits of the California Cancer Registry
June 06, 2017
Dr Matthew Gubens Outlines Exciting Directions for Lung Cancer Immunotherapy Research
May 20, 2017
Dr Moon S. Chen Jr on the Attitudes Needed to Design Population Health Interventions
May 13, 2017
Dr Shauntice Allen Discusses Community Engagement in Public Health Research
April 28, 2017
Dr Shaji Kumar Discusses Biological Foundations of New Multiple Myeloma Research
April 24, 2017
Dr Matthew Gubens: Multidisciplinary Approach Can Help Oncologists Tackle Immunotherapy Toxicities
April 21, 2017
Dr Moon S. Chen Jr: Culture and Behavior as Population Determinants of Cancer Outcomes
April 16, 2017
Helping Cancer Patients Quit Smoking Through Counseling and Pharmacotherapy
March 26, 2017
Dr Shauntice Allen Explains Community-Level Factors Contributing to Cancer Disparities
March 25, 2017
Dr Shaji Kumar: Advances and Opportunities in Treating Multiple Myeloma
March 25, 2017
Personalized Care in Lung Cancer Is All About the Molecular Subtype
March 24, 2017
Currently Reading
Radiation Therapy Updates for Breast Cancer in the NCCN Guidelines
March 24, 2017
Dr Moon S. Chen Jr Discusses Strategies for Reducing Cancer Disparities in Asian Americans
March 23, 2017
Multigene Panels Important for Precision Cancer Care, Variance and Coverage Barriers Remain
March 23, 2017
Addressing the Roots of Disparities in Cancer Care: Inherent Bias, Resources, and Insurance
March 23, 2017

Radiation Therapy Updates for Breast Cancer in the NCCN Guidelines

Surabhi Dangi-Garimella, PhD
On the second day of the 22nd Annual Conference of the National Comprehensive Cancer Network (NCCN), Kilian E. Salerno, MD, of the Roswell Park Cancer Institute, walked the audience through updates to the NCCN Guidelines, explaining clinical situations in which radiation is indicated, appropriate targets of radiation treatment, and optimal approaches for minimizing toxicity.

“Identifying an appropriate margin has been a topic of debate and the new Guideline provides direction,” said Salerno. “We must remember, though, that context matters.” The following 2 recommendations have been added to the Guideline:
  • 2 mm is considered an adequate margin in ductal carcinoma in situ treated with whole-breast irradiation.
  • For stage 1-II invasive disease treated with whole-breast irradiation, no tumor on ink is considered an adequate margin

Salerno then spoke about locoregional treatment of clinical stage I, IIA, or IIIB disease or node-positive disease. For negative axillary nodes the following treatment options have been recommended:
  • Radiation therapy to the whole breast, with or without boost to the tumor bed; preferably hypofractionation
  • Accelerated partial breast irradiation in some low-risk patients, following guidelines defined by the American Society of Radiation Oncology, which, Salerno said, will be updated in the coming year.

She then provided insight on post mastectomy radiation (PMRT), classic indications for which include 4 or more positive axillary lymph nodes, positive margins, and tumor size over 5 cm. However, patients with 1 to 3 lymph nodes, close margins and some high-risk features, such as age, extracapsular extension, and certain intrinsic subtypes, could also be considered for PMRT.

Regional node irradiation or RNI is recommended for those with 4 or more positive nodes, strongly considered for 1 to 3 positive nodes, and may be considered for some high-risk node negative patients.


 
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!